Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of hepatitis D

Informazioni relative al progetto

D-SOLVE

ID dell’accordo di sovvenzione: 101057917

DOI

10.3030/101057917

Data della firma CE 25 Maggio 2022

Data di avvio 1 Ottobre 2022

Data di completamento 30 Settembre 2026

Finanziato da

• Health

Costo totale

€ 6 754 010,00

Contributo UE

€ 6 754 010,00

Coordinato da

MEDIZINISCHE HOCHSCHULE HANNOVER
Germany

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (12)

Plan for dissemination and exploitation of results (M6)

A strategic plan for the dissemination and exploitation of results is available.

Project website, brochure, logo, Twitter account

Project website will be launched.Information material as a brochure will be available.A consortium logo will be ready.Social media accounts will be implemented.

Established of fine-needle aspiration protocol and training of physicians at all clinical site

SOP document; training workshop for trial staff

Data Management Plan

The plan outlines all the data that will be collected and generated during the project, how it will be created, stored and backed-up, who owns it and who is responsible for the different data and which data will be preserved and shared, according to the participation of the project in the Open Data Research Pilot.

Promotional literature (e.g. leaflets, slide deck) with information about the project to be used as a communication tool at scientific events and workshops attended by consortium members

Additional promotional literature (e.g. leaflets, slide deck) with information about the project to be used as a communication tool at scientific events and workshops attended by consortium members are designed and available

General project Management Plan

Project internal management plan, elaborating on relevant internal procedures and responsibilities, rules and guidelines, and clarifying baseline EC requirements for effective and efficient collaboration, communication and dissemination - guidelines and templates for the execution of the project included.

Finalization of the study protocol of the bulevirtide stop trial including ethics submission

Study protocol, proof of ethic submission

Clinical protocol and establishment of the redcap electronic case-report form

Protocol document, redcap ECRF-form online available for HDV 750 cohort.

New attack methods and their implementation

A document describing method/algorithms on the potential attacks for the system, and their software implementation

D-SOLVE academy established

The D-SOLVE academy will be founded to enable exchange between D-SOLVE centers. The concept of the academy will be agreed on and be implemented at M12.

Implementation of an Ethics & Scientific Advisory Board (ESAB), a Data Safety Monitoring Board (in cooperation with WP6) for the clinical trial (DSMB), and an Innovation Management Board (IMB)
Attack evaluation results

A document summarizing the experimental evaluation for the attacks from D6.2

Pubblicazioni

Peer reviewed articles (36)

Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐<scp>IFNα</scp>‐2a as Treatment for Chronic Hepatitis Delta

Autori: Pietro Lampertico, Pavel O. Bogomolov, Vladimir Chulanov, Tatiana Stepanova, Viacheslav Morozov, Lena Allweiss, Maura Dandri, Jürgen Burhenne, Antje Blank, Sandra Ciesek, Carina Elsner, Ulf Dittmer, Qi An, Dmitry Manuilov, Ben L. Da, John F. Flaherty, Stephan Urban, Heiner Wedemeyer
Pubblicato in: Liver International, Numero 45, 2025, ISSN 1478-3223
Editore: Wiley
DOI: 10.1111/LIV.70008

Inflammation-related prognostic markers in resected hepatocellular carcinoma.

Autori: Giannone F, Slovic N, Pessaux P, Schuster C, Baumert TF, Lupberger J.
Pubblicato in: Front. Oncol, 2023, ISSN 2234-943X
Editore: Frontiers Media S. A.
DOI: 10.3389/fonc.2023.1267870

Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta

Autori: Elisabetta Degasperi, Caroline Scholtes, Barbara Testoni, Sara Uceda Renteria, Maria Paola Anolli, Caroline Charre, Floriana Facchetti, Marie-Laure Plissonnier, Dana Sambarino, Riccardo Perbellini, Sara Monico, Annapaola Callegaro, Ester García-Pras, Sabela Lens, Maria Francesca Cortese, Xavier Forns, Sofía Pérez-del-Pulgar, Marintha Heil, Massimo Levrero, Fabien Zoulim, Pietro Lampertico
Pubblicato in: Journal of Hepatology, Numero 82, 2025, ISSN 0168-8278
Editore: Elsevier BV
DOI: 10.1016/J.JHEP.2024.11.051

Hepatitis D virus—still the devil!

Autori: Anika Wranke, Heiner Wedemeyer
Pubblicato in: Hepatology, Numero 81, 2025, ISSN 0270-9139
Editore: Ovid Technologies (Wolters Kluwer Health)
DOI: 10.1097/HEP.0000000000001144

Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide

Autori: Pierluigi Toniutto, Edmondo Falleti, Sara Cmet, Annarosa Cussigh, Elisabetta Degasperi, Maria Paola Anolli, Dana Sambarino, Floriana Facchetti, Marta Borghi, Riccardo Perbellini, Sara Monico, Pietro Lampertico
Pubblicato in: Journal of Hepatology, Numero 81, 2025, ISSN 0168-8278
Editore: Elsevier BV
DOI: 10.1016/J.JHEP.2024.06.013

Droplet Digital PCR: A Powerful Tool for Accurate Quantification of Hepatitis D Virus RNA Levels and Verification of Detection Limits

Autori: L. Sandmann, L. Windzio, B. Bremer, S. Falak, J. Beheim‐Schwarzbach, A. Kummrow, M. Cornberg, H. Wedemeyer, B. Maasoumy, E. Valiente
Pubblicato in: Journal of Viral Hepatitis, Numero 32, 2025, ISSN 1352-0504
Editore: Wiley
DOI: 10.1111/JVH.70036

Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies

Autori: Pietro Lampertico, Maria Paola Anolli, Dominique Roulot, Heiner Wedemeyer
Pubblicato in: Gut, Numero 74, 2025, ISSN 0017-5749
Editore: BMJ
DOI: 10.1136/GUTJNL-2024-332597

Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta

Autori: Jachs M, Sandmann L, Hartl L, Tergast T, Schwarz M, Bauer DJM, Balcar L, Ehrenbauer A, Hofer BS, Cornberg M, Lenzen H, Deterding K, Trauner M, Mandorfer M, Wedemeyer H, Reiberger T, Maasoumy B.
Pubblicato in: Journal of Hepatology, 2024, ISSN 1600-0641
Editore: Journal of Hepatology
DOI: 10.1016/j.jhep.2024.03.005

TIGIT expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D

Autori: Po-Chun Chen, Katja Deterding, Sophie Anna Engelskircher, Kerstin Port, Lisa Sandmann, Athira Chakkadath, Tijana Ristic, Qingyu Wu, Birgit Bremer, Anke R.M. Kraft, Markus Cornberg, Albert Heim, Helenie Kefalakes, Niklas K. Björkström, Norman Woller, Heiner Wedemeyer
Pubblicato in: Hepatology, 2025, ISSN 0270-9139
Editore: Ovid Technologies (Wolters Kluwer Health)
DOI: 10.1097/HEP.0000000000001238

Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV

Autori: Maria Paola Anolli, Sara Uceda Renteria, Elisabetta Degasperi, Floriana Facchetti, Dana Sambarino, Marta Borghi, Riccardo Perbellini, Roberta Soffredini, Sara Monico, Annapaola Callegaro, Pietro Lampertico
Pubblicato in: JHEP Reports, Numero 7, 2025, ISSN 2589-5559
Editore: Elsevier BV
DOI: 10.1016/J.JHEPR.2024.101299

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection.

Autori: Sandmann L, Degasperi E, Port K, Aleman S, Wallin JJ, Manuilov D, Da BL, Cornberg M, Lampertico P, Maasoumy B, Wedemeyer H, Deterding K
Pubblicato in: Aliment Pharmacol Ther, 2024, ISSN 1365-2036
Editore: Aliment Pharmacol Ther
DOI: 10.1111/apt.17878

Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024

Autori: Elisabetta Degasperi, Lisa Sandmann, Heiner Wedemeyer, Pietro Lampertico, null null
Pubblicato in: Liver International, Numero 45, 2025, ISSN 1478-3223
Editore: Wiley
DOI: 10.1111/LIV.70189

Memories of Stress: The Imprinted Cancer Risk After HCV Cure

Autori: Lupberger, Joachim; Baumert, Thomas F.
Pubblicato in: Cellular and Molecular Gastroenterology and Hepatology, 2023, ISSN 2352-345X
Editore: Elsevier Inc.
DOI: 10.1016/j.jcmgh.2023.05.006

Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA

Autori: Deterding K, Xu C, Port K, Dietz-Fricke C, Xun J, Maasoumy B, Cornberg M, Wedemeyer H.
Pubblicato in: J Viral Hepat., 2023, ISSN 1352-0504
Editore: Blackwell Publishing Inc.
DOI: 10.1111/jvh.13831.

"Antiviral Therapy of Chronic Hepatitis D Virus Infection - Addendum to the S3 Guideline ""Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection"" of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS)"

Autori: Sandmann L, Berg T, Deterding K, Fischer N, Hinrichsen H, Petersen J, Tacke F, Cornberg M
Pubblicato in: Zeitschrift für Gastroenterologie, 2023, ISSN 0044-2771
Editore: Georg Thieme Verlag
DOI: 10.1055/a-2181-3345

Five‐year follow‐up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

Autori: Olympia E. Anastasiou, Florin A. Caruntu, Manuela G. Curescu, Kendal Yalcin, Ulus S. Akarca, Selim Gürel, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George V. Papatheodoridis, Onur Keskin, Kerstin Port, Monica Radu, Mustafa K. Celen, Ramazan Idilman, Benjamin Heidrich, Ingmar Mederacke, Heiko von der Leyen, Julia Kahlhöfer, Maria von Karpowitz, Svenja Hardtke, Markus Cornberg, Cihan Yurdaydin, Heiner Wedemeyer
Pubblicato in: Liver International, Numero 44, 2024, ISSN 1478-3223
Editore: Wiley
DOI: 10.1111/LIV.15745

Quality of life improves during antiviral therapy with bulevirtide

Autori: Julia Carolin Eichholz, Christopher Dietz-Fricke, Simon Kristian Mrowietz, Katja Dinkelborg, Kerstin Port, Heiner Wedemeyer, Katja Deterding
Pubblicato in: Zeitschrift für Gastroenterologie, Numero 63, 2025, ISSN 0044-2771
Editore: Georg Thieme Verlag KG
DOI: 10.1055/A-2633-6361

Unraveling the genetic susceptibility to HBV-related liver cancer: The role of virus–host immune interactions

Autori: Pierre Tonnerre, Yujin Hoshida, Thomas F. Baumert
Pubblicato in: Hepatology, 2025, ISSN 0270-9139
Editore: Ovid Technologies (Wolters Kluwer Health)
DOI: 10.1097/HEP.0000000000001355

An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infection

Autori: Atish Mukherji, Frank Jühling, Yogy Simanjuntak, Emilie Crouchet, Fabio Del Zompo, Yuji Teraoka, Alexandre Haller, Philippe Baltzinger, Soumith Paritala, Fahmida Rasha, Naoto Fujiwara, Cloé Gadenne, Nevena Slovic, Marine A. Oudot, Sarah C. Durand, Clara Ponsolles, Catherine Schuster, Xiaodong Zhuang, Jacinta Holmes, Ming-Lun Yeh, Hiromi Abe-Chayama, Mathias Heikenwälder, Angelo Sangiovanni, Massimo Iavarone, Massimo Colombo, Steven K. H. Foung, Jane A. McKeating, Irwin Davidson, Ming-Lung Yu, Raymond T. Chung, Yujin Hoshida, Kazuaki Chayama, Joachim Lupberger, Thomas F. Baumert
Pubblicato in: Nature Communications, Numero 15, 2024, ISSN 2041-1723
Editore: Springer Science and Business Media LLC
DOI: 10.1038/S41467-024-51698-8

Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022

Autori: Lampertico P, Degasperi E, Sandmann L, Wedemeyer H; Delta Cure 2022 Working Group
Pubblicato in: JHEP Reports, 2023, ISSN 2589-5559
Editore: JHEP Reports
DOI: 10.1016/j.jhepr.2023.100818

Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection.

Autori: Wranke A, Heidrich B, Deterding K, Hupa-Breier KL, Kirschner J, Bremer B, Cornberg M, Wedemeyer H.
Pubblicato in: Hepatol Int., 2023, ISSN 1936-0541
Editore: Hepatol Int.
DOI: 10.1007/s12072-023-10575-0

HDV RNA Assays Writing Group at the HBV Forum. HDV RNA assays: Performance characteristics, clinical utility, and challenges

Autori: Wedemeyer H, Leus M, Battersby TR, Glenn J, Gordien E, Kamili S, Kapoor H, Kessler HH, Lenz O, Lütgehetmann M, Mixson-Hayden T, Simon CO, Thomson M, Westman G, Miller V, Terrault N, Lampertico P
Pubblicato in: Hepatology, 2023, ISSN 0270-9139
Editore: John Wiley & Sons Inc.
DOI: 10.1097/HEP.0000000000000584

Value and Kinetics of Virological Markers in the Natural Course of Chronic Hepatitis D Virus Infection

Autori: Lisa Sandmann, Valerie Ohlendorf, Alena Ehrenbauer, Birgit Bremer, Anke R. M. Kraft, Markus Cornberg, Katja Deterding, Heiner Wedemeyer, Benjamin Maasoumy
Pubblicato in: Liver International, Numero 45, 2025, ISSN 1478-3223
Editore: Wiley
DOI: 10.1111/LIV.70003

Sequence analysis of the hepatitis D virus across genotypes reveals highly conserved regions amidst evidence of recombination

Autori: Shruti Chowdhury, Carina Jacobsen, Daniel P Depledge, Heiner Wedemeyer, Lisa Sandmann, Helenie Kefalakes
Pubblicato in: Virus Evolution, Numero 11, 2025, ISSN 2057-1577
Editore: Oxford University Press (OUP)
DOI: 10.1093/VE/VEAF012

Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.

Autori: Dietz-Fricke C, Degasperi E, Jachs M, Maasoumy B, Reiter FP, Geier A, Grottenthaler JM, Berg CP, Sprinzl K, Zeuzem S, Gödiker J, Schlevogt B, Herta T, Wiegand J, Soffredini R, Wedemeyer H, Deterding K, Reiberger T, Lampertico P.
Pubblicato in: Hepatology, 2024, ISSN 0270-9139
Editore: John Wiley & Sons Inc.
DOI: 10.1097/HEP.0000000000000847

Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection

Autori: Svenja Hardtke, Cihan Yurdaydin, Florin A. Caruntu, Manuela G. Curescu, Kendal Yalcin, Ulus S. Akarca, Selim Gürel, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George V. Papatheodoridis, Kerstin Port, Michael P. Manns, Markus Cornberg, Julia Kahlhöfer, Heiner Wedemeyer
Pubblicato in: Journal of Viral Hepatitis, Numero 32, 2025, ISSN 1352-0504
Editore: Wiley
DOI: 10.1111/JVH.70022

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

Autori: Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Manuilov D, Suri V, An Q, Da B, Flaherty J, Osinusi A, Liu Y, Merle U, Schulze Zur Wiesch J, Zeuzem S
Pubblicato in: NEJM, 2023, ISSN 0028-4793
Editore: Massachusetts Medical Society
DOI: 10.1056/NEJMoa2213429

Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models

Autori: Romain Desert, Fabio Gianonne, Antonio Saviano, Yujin Hoshida, Mathias Heikenwälder, Pierre Nahon, Thomas F. Baumert
Pubblicato in: npj Gut and Liver, Numero 2, 2025, ISSN 3004-9806
Editore: Springer Science and Business Media LLC
DOI: 10.1038/S44355-025-00018-Y

Natural history of untreated HDV patients: Always a progressive disease?

Autori: Kamal H, Aleman S; D-SOLVE Consortium
Pubblicato in: Liver International, 2023, ISSN 1478-3223
Editore: Liver International
DOI: 10.1111/liv.15467

Treating hepatitis D with bulevirtide – Real-world experience from 114 patients

Autori: Christopher Dietz-Fricke; Frank Tacke; Caroline Zöllner; Münevver Demir; Hartmut H. Schmidt; Christoph Schramm; Katharina Willuweit; Christian M. Lange; Sabine Weber; Gerald Denk; Christoph P. Berg; Julia M. Grottenthaler; Uta Merle; Alexander Olkus; Stefan Zeuzem; Kathrin Sprinzl; Thomas Berg; Florian van Bömmel; Johannes Wiegand; Toni Herta; Thomas Seufferlein; Eugen Zizer; Nektarios Dikopoulos; Robert Thimme; Christoph Neumann-Haefelin; Peter R. Galle; Martin Sprinzl; Ansgar W. Lohse; Julian Schulze zur Wiesch; Jan Kempski; Andreas Geier; Florian P. Reiter; Bernhard Schlevogt; Juliana Gödiker; Wolf Peter Hofmann; Peter Buggisch; Julia Kahlhöfer; Kerstin Port; Benjamin Maasoumy; Markus Cornberg; Heiner Wedemeyer; Katja Deterding
Pubblicato in: JHEP Reports, 2023, ISSN 2589-5559
Editore: JHEP Reports
DOI: 10.1016/J.JHEPR.2023.100686

Long‐term outcome of hepatitis delta in different regions world‐wide: Results of the Hepatitis Delta International Network

Autori: Anika Wranke, Cirley Lobato, Emanoil Ceausu, George N. Dalekos, Mario Rizzetto, Adela Turcanu, Grazia A. Niro, Onur Keskin, George Gherlan, Minaam Abbas, Patrick Ingiliz, Marion Muche, Maria Buti, Mathias Jachs, Thomas Vanwolleghem, Markus Cornberg, Zaigham Abbas, Cihan Yurdaydin, Petra Dörge, Heiner Wedemeyer, null null
Pubblicato in: Liver International, Numero 44, 2025, ISSN 1478-3223
Editore: Wiley
DOI: 10.1111/LIV.16006

Unraveling the liver antiviral immunity in functional cure of chronic hepatitis B using scRNAseq

Autori: Pierre Tonnerre, Thomas F. Baumert
Pubblicato in: Journal of Hepatology, Numero 81, 2024, ISSN 0168-8278
Editore: Elsevier BV
DOI: 10.1016/J.JHEP.2024.03.017

Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis

Autori: Elisabetta Degasperi, Maria Paola Anolli, Mathias Jachs, Thomas Reiberger, Victor De Ledinghen, Sophie Metivier, Gianpiero D’Offizi, Francesco di Maria, Christoph Schramm, Hartmut Schmidt, Caroline Zöllner, Frank Tacke, Christopher Dietz-Fricke, Heiner Wedemeyer, Margarita Papatheodoridi, George Papatheodoridis, Ivana Carey, Kosh Agarwal, Florian Van Bömmel, Maurizia R. Brunetto, Mariana Cardoso, Gabriella Verucchi, Alessia Ciancio, Fabien Zoulim, Soo Aleman, Nasser Semmo, Alessandra Mangia, Marie-Noelle Hilleret, Uta Merle, Teresa A. Santantonio, Nicola Coppola, Adriano Pellicelli, Bruno Roche, Xavier Causse, Louis D’Alteroche, Jérome Dumortier, Nathalie Ganne, Frederic Heluwaert, Isabelle Ollivier, Dominique Roulot, Mauro Viganò, Alessandro Loglio, Alessandro Federico, Francesca Pileri, Monia Maracci, Matteo Tonnini, Jean-Pierre Arpurt, Karl Barange, Eric Billaud, Stanislas Pol, Anne Gervais, Anne Minello, Isabelle Rosa, Massimo Puoti, Pietro Lampertico
Pubblicato in: Journal of Hepatology, Numero 82, 2025, ISSN 0168-8278
Editore: Elsevier BV
DOI: 10.1016/J.JHEP.2024.12.044

Quality‐of‐life scores improve after 96 weeks of <scp>PEG‐IFNa</scp>‐2a treatment of hepatitis D: An analysis of the <scp>HIDIT‐II</scp> trial

Autori: Katja Dinkelborg, Julia Kahlhöfer, Petra Dörge, Cihan Yurdaydin, Svenja Hardtke, Florin Alexandru Caruntu, Manuela G. Curescu, Kendal Yalcin, Ulus S. Akarca, Selim Gürel, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George V. Papatheodoridis, Onur Keskin, Kerstin Port, Monica Radu, Mustafa K. Celen, Ramazan Idilman, Kristina Weber, Judith Stift, Ulrike Wittkop, Benjamin Heidrich, Ingmar Mederacke, Heiko von der Leyen, Hans Peter Dienes, Markus Cornberg, Armin Koch, Michael P. Manns, Heiner Wedemeyer, Katja Deterding, null null
Pubblicato in: Liver International, Numero 43, 2023, ISSN 1478-3223
Editore: Wiley
DOI: 10.1111/LIV.15602

Letter to the Editor: The WHO HDV RNA international standard does not reflect variability of real-world samples

Autori: Lisa Sandmann, Birgit Bremer, Katja Deterding, Kerstin Port, Beatrix Gey, Christian Früchtel, André Reinhardt, Ingolf Lachmann, Markus Cornberg, Helenie Kefalakes, Benjamin Maasoumy, Heiner Wedemeyer
Pubblicato in: Hepatology, Numero 81, 2025, ISSN 0270-9139
Editore: Ovid Technologies (Wolters Kluwer Health)
DOI: 10.1097/HEP.0000000000000975

Targeting immuno-metabolism and anti-viral immune responses in chronic hepatitis B

Autori: Suzanne Faure-Dupuy, Thomas F. Baumert
Pubblicato in: Hepatology International, Numero 17, 2023, ISSN 1936-0533
Editore: Springer Science and Business Media LLC
DOI: 10.1007/S12072-023-10546-5

Conference proceedings (3)

Understanding Data Importance in Machine Learning Attacks: Does Valuable Data Pose Greater Harm?

Autori: Rui Wen, Michael Backes, Yang Zhang
Pubblicato in: Proceedings 2025 Network and Distributed System Security Symposium, 2025
Editore: Internet Society
DOI: 10.14722/NDSS.2025.230331

SoK: Data Reconstruction Attacks Against Machine Learning Models: Definition, Metrics, and Benchmark

Autori: Rui Wen, Yiyong Liu, Michael Backes, Yang Zhang
Pubblicato in: Proceedings of the 34th USENIX Security Symposium is sponsored by USENIX, 2025
Editore: USENIX Association
DOI: 10.5281/ZENODO.15603060

SecurityNet: Assessing Machine Learning Vulnerabilities on Public Models

Autori: Boyang Zhang, Zheng Li, Ziqing Yang, Xinlei He, Michael Backes, Mario Fritz, Yang Zhang
Pubblicato in: Proceedings des 33rd USENIX Security Symposium (2024), 2024
Editore: USENIX Association
DOI: 10.48550/ARXIV.2310.12665